Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 51Multiple Myeloma 42Lymphoma 42Neoplasm Metastasis 41Lung Neoplasms 38Breast Neoplasms 38Prostatic Neoplasms 32Carcinoma, Non-Small-Cell Lung 31Leukemia, Myeloid, Acute 30Colorectal Neoplasms 28Melanoma 27Ovarian Neoplasms 26Hematologic Neoplasms 24Pancreatic Neoplasms 22Urinary Bladder Neoplasms 21Lymphoma, Non-Hodgkin 21Glioma 21Carcinoma, Renal Cell 19Sarcoma 18Myelodysplastic Syndromes 16Burkitt Lymphoma 16Triple Negative Breast Neoplasms 15Stomach Neoplasms 15Neuroblastoma 14Colonic Neoplasms 14Brain Neoplasms 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma, Large B-Cell, Diffuse 13Leukemia, Lymphocytic, Chronic, B-Cell 13Fallopian Tube Neoplasms 13

Interventions

pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1merphos 1durvalumab 1Vinblastine 1Specimen Handling 1Platinum 1Methotrexate 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Gemcitabine 1Doxorubicin 1Disulfides 1Cisplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Renal Pelvis and Ureter Urothelial Carcinoma × 30 days × Clear all
NCT04628767 2026-06-03

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

National Cancer Institute (NCI)

Phase 2/3 Recruiting
131 enrolled
Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡